PeptidePedia The community reference

Contributions of CagriCass

User contributions·25 logged edits·page 1 of 1

Contributions by CagriCass, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 2,499 edits includes activity predating the current log.

  1. 09:15, 26 Jun 2026 (diff | hist) Talk:CagriSema 822 +72 /* The under-titration question */ reply
  2. 10:05, 25 Jun 2026 (diff | hist) Talk:CagriSema 400 +224 /* The under-titration question */ new section
  3. 06:03, 13 Jun 2026 (diff | hist) Fasting insulin 4,198 ±0 fix the anchor on an internal link
  4. 09:40, 5 Mar 2026 (diff | hist) Talk:Cagrilintide 400 +154 /* Calcitonin receptor engagement */ new section
  5. 12:39, 3 Mar 2026 (diff | hist) Liraglutide 5,967 ±0 m add the molecular formula to the infobox
  6. 16:33, 18 Feb 2026 (diff | hist) Cold chain 27,220 ±0 expand §Failure modes
  7. 07:18, 21 Nov 2025 (diff | hist) SUSTAIN trial programme 5,153 ±0 state that the trial has reported but is not yet peer-reviewed
  8. 03:19, 16 Oct 2025 (diff | hist) Triple agonist 4,269 ±0 add the structural figure and caption it properly
  9. 06:30, 22 Sep 2025 (diff | hist) Exenatide 5,754 +223 m add the excipient list from the labelling
  10. 15:31, 13 Sep 2025 (diff | hist) CagriSema 5,687 +385 fix the amino-acid substitution — position 8, not position 2
  11. 02:41, 14 Aug 2025 (diff | hist) Oral semaglutide 4,349 ±0 rm the comparison to a compound with no published head-to-head data
  12. 22:14, 13 Aug 2025 (diff | hist) Lixisenatide 4,195 +138 m rm a duplicated category
  13. 08:12, 5 Jun 2025 (diff | hist) Retatrutide 5,894 ±0 m correct the molar mass — source gives the free-base figure, we had the salt
  14. 17:55, 23 May 2025 (diff | hist) TRIUMPH trial programme 4,035 +21 label the extension study as an extension study in the table
  15. 20:52, 30 Mar 2025 (diff | hist) Exenatide 4,288 ±0 unpipe a link that did not need piping
  16. 16:48, 8 Feb 2025 (diff | hist) Timeline of incretin therapeutics 3,151 ±0 m give the INN alongside the trade name at first mention
  17. 01:42, 4 Jan 2025 (diff | hist) Amylin 3,826 +132 m state plainly that the research-use-only form is not approved for human use
  18. 22:48, 14 Dec 2024 (diff | hist) Triple agonist 2,546 ±0 expand §Consequences of the glucagon arm
  19. 09:52, 29 Nov 2024 (diff | hist) International nonproprietary name 2,241 +178 space between number and unit per PP:MOS
  20. 04:30, 5 Nov 2024 (diff | hist) Retatrutide 4,077 +170 correct the dose ladder — the maintenance dose is not the maximum dose
  21. 11:14, 10 Oct 2024 (diff | hist) International nonproprietary name 1,106 ±0 de-duplicate a repeated sentence
  22. 18:59, 13 Sep 2024 (diff | hist) Research use only 3,193 +314 m split the compounding position from the manufacturing position
  23. 17:13, 7 Sep 2024 (diff | hist) Amylin 1,269 ±0 the half-life in the lead was the terminal figure; label it as such
  24. 00:53, 3 Sep 2024 (diff | hist) SURPASS trial programme 2,281 +288 fix a dangling clause
  25. 07:42, 23 Aug 2024 (diff | hist) GLP-1 receptor agonist 5,413 +492 alphabetise the see-also list